Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Doxazosin

Klassificering: A

Preparat: Alfadil, Alfadil®, Alfadil® BPH, Cardura, Cardura BPH, Carduran, Doxacor, Doxazosin 2care4, Doxazosin Actavis, Doxazosin Arrow, Doxazosin Mylan, Doxazosin NM Pharma, Doxazosin ratiopharm, Doxazosin Sandoz, Doxazosin Stada, Doxazosin STADA®, Doxazosin Uro, Doxazosin-ratiopharm, Doxazosin-Ratiopharm

ATC kod: C02CA04

Substanser: doxazosin, doxazosinmesilat

Sammanfattning

Doxazosin har indikationen högt blodtryck hos kvinnor och män, samt benign prostatahyperplasi hos män. Den blodtryssänkande effekten av doxazosin är likvärdig hos kvinnor och män.

Additional information

Pharmacokinetics and dosing

No clinically relevant sex differences in pharmacokinetics have been observed at steady state with of 4 mg doxazosin once daily in a controlled-release gastrointestinal therapeutic system formulation (GITS) [1-3]. The Cmax and AUC were approximately 20% higher in women than men at steady state. However, after a single 4 mg dose, the Cmax and AUC 45% and 46% higher in women [3]. In a similar study stratified by age groups, the sex difference was only seen in the young group. Young women had higher Cmax and AUC than the rest of the study population; the AUC was 45% higher on day 1 (p<0.05) and 20% higher in day 7 when compared to young men. Further, the highest number of adverse effects were reported in young women, however the number of adverse effects declined with time and steady state was achieved [3]. Based on this, FDA’s clinical pharmacology reviewer considered that young women would benefit from dose-titration at doses lower than 4 mg due to the disproportionate high number of adverse effects and the sex differences in pharmacokinetic parameters. However, the 4 mg GITS is the lowest available dose, making dose titration not possible in young women. Further, the sex difference in AUC was possible due to a lower body weight in women [3]. In spite of this, no dose adjustment  according to sex [2] or age [3] is recommended.

Effects

In a clinical trial (74 men, 38 women) examining the effects of doxazosin 1 mg daily in patients with mild hypertension, blood pressure were reduced to a similar extent in men and women [4]. Also, doxazosin is used to reduce symptoms of benign prostatic hyperplasia in men [5].

Adverse effects

Clinical studies report that the type and incidence of adverse events from doxazosin were similar in men and women [1, 6]. However, there have been indications of an association between higher drug concentration and a higher risk of adverse events in women (see above under Pharmacokinetics and dosing).

Reproductive health issues

Regarding teratogenic aspects, please consult the Drugs and Birth Defects Database (in Swedish, Janusmed fosterpåverkan).

Other information

Several clinical trials have shown good results with the use of α1-blockers in the treatment of lower ureteral stones [6, 7]. A comparative prospective study (40 men, 40 women) evaluated the effects of doxazosin 4 mg once daily in patients with distal ureteral stones. The results showed no statistically significant difference in expulsion time, expulsion rate, and numbers of renal colic episodes among men and women. Safety and tolerability of the therapy were considered to be same in both sexes [6].

Doxazosin is used in men with erectile dysfunction, however with varying results [8].

Försäljning på recept

Fler män än kvinnor hämtade ut tabletter innehållande doxazosin (ATC-kod C02CA04) på recept i Sverige år 2018, totalt 20 738 män och 7 400 kvinnor. Det motsvarar 4,1 respektive 1,5 personer per tusen invånare. Andelen som hämtat ut läkemedel var högst i åldersgruppen 70 år och äldre hos båda könen. I genomsnitt var tabletter innehållande doxazosin 2,8 gånger vanligare hos män [9].

Uppdaterat: 2019-04-08

Litteratursökningsdatum: 2019-03-06

Referenser

  1. Chung M, Vashi V, Puente J, Sweeney M, Meredith P. Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation. Br J Clin Pharmacol. 1999;48:678-87. PubMed
  2. Kwon YH, Gwak HS, Yoon SJ, Chun IK. Pharmacokinetics of doxazosin gastrointestinal therapeutic system after multiple administration in Korean healthy volunteers. Drug Dev Ind Pharm. 2007;33:824-9. PubMed
  3. Clinical Pharmacology and Biopharmaceutics Review - CARDURA XL (doxazosin mesylate). Drugs@FDA [www]. Food and Drug Administration (FDA). [updated 2005-02-22, cited 2019-03-06]. länk
  4. Pickering TG, Levenstein M, Walmsley P. Differential effects of doxazosin on clinic and ambulatory pressure according to age, gender, and presence of white coat hypertension Results of the HALT Study Hypertension and Lipid Trial Study Group. Am J Hypertens. 1994;7:848-52. PubMed
  5. Doggrell SA. After ALLHAT: doxazosin for the treatment of benign prostatic hyperplasia. Expert Opin Pharmacother. 2004;5:1957-64. PubMed
  6. Resorlu B, Bozkurt OF, Senocak C, Unsal A. Effectiveness of doxazosin in the management of lower ureteral stones in male and female patients. Int Urol Nephrol. 2011;43:645-9. PubMed
  7. Aydogdu O, Burgu B, Gucuk A, Suer E, Soygur T. Effectiveness of doxazosin in treatment of distal ureteral stones in children. J Urol. 2009;182:2880-4. PubMed
  8. van Dijk MM, de la Rosette JJ, Michel MC. Effects of alpha(1)-adrenoceptor antagonists on male sexual function. Drugs. 2006;66:287-301. PubMed
  9. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2018 [cited 2019-03-08.] länk

Författare: Linnéa Karlsson Lind

Faktagranskat av: Mia von Euler

Godkänt av: Karin Schenck-Gustafsson